


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 453/02, A61K 31/435		A1	(11) International Publication Number: WO 98/57972
			(43) International Publication Date: 23 December 1998 (23.12.98)
(21) International Application Number: PCT/EP98/03500 (22) International Filing Date: 5 June 1998 (05.06.98) (30) Priority Data: 9712882.1 18 June 1997 (18.06.97) GB (71) Applicant (for GB only): PFIZER LIMITED [GB/GB]; Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). (71) Applicant (for all designated States except GB US): PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): MONAGHAN, Sandra, Marina [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). ALKER, David [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). BURNS, Christopher, John [AU/AU]; The University of Sydney, School of Chemistry, Building F11, Sydney, NSW 2006 (AU). (74) Agents: RUDDOCK, Keith, Stephen et al.; Pfizer Limited, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).			(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: QUATERNARY AMMONIUM COMPOUNDS AS TACHYKININ ANTAGONISTS



(57) Abstract

The present invention provides a compound of formula (I) wherein R is phenyl, C₃-C₇ cycloalkyl or heteroaryl, each of which being optionally benzo- or C₃-C₇ cycloalkyl-fused and optionally substituted, including in the benzo- or C₃-C₇ cycloalkyl-fused portion, by from 1 to 3 substituents each independently selected from C₁-C₄ alkyl, fluoro(C₁-C₄)alkyl, C₁-C₄ alkoxy, fluoro(C₁-C₄)alkoxy, phenoxy, C₂-C₄ alkanoyl, halo, C₁-C₄ alkoxycarbonyl, C₃-C₇ cycloalkyl, -S(O)_m(C₁-C₄ alkyl), cyano, -NR²R³, -S(O)_mNR²R³, -NR⁴(C₁-C₄ alkanoyl) and -CONR²R³, or R is 2,3-dihydrobenzo[b]furanyl or chromanyl; R¹ is H or C₁-C₆ alkyl; W is a direct link, methylene or ethylene; X is unbranched C₂-C₄ alkylene; Y is phenyl, naphthyl, benzyl, pyridyl, thienyl or C₃-C₇ cycloalkyl, each of which being optionally substituted by from 1 to 3 substituents each independently selected from C₁-C₄ alkyl, fluoro(C₁-C₄)alkyl, C₁-C₄ alkoxy, fluoro(C₁-C₄)alkoxy, halo and cyano; Ar is phenyl, naphthyl, benzyl, thienyl, benzo[b]thienyl or indolyl, each of which being optionally substituted by from 1 to 3 substituents each independently selected from C₁-C₄ alkyl, fluoro(C₁-C₄)alkyl, C₁-C₄ alkoxy, fluoro(C₁-C₄)alkoxy, halo and cyano, or Ar is 1,3-benzodioxolan-4 or 5-yl or 1,4-benzodioxan-5 or 6-yl; Z^A is a pharmaceutically acceptable anion; with the proviso that when W is a direct link and R is optionally fused and optionally substituted heteroaryl, said heteroaryl is linked by a ring carbon atom to the carbonyl group. The compounds are tachykinin antagonists.